Global partnership to improve diagnostic accuracy of breast cancer

A new partnership aims to advance AI-enabled digital pathology for end-to-end breast tumour profiling

PathPresenter, a digital pathology platform and 4D Path, a Boston company producing computer-aided cancer diagnostic products, are announcing a global partnership to distribute 4D Q-plasia OncoReader Breast within the new clinical workflow platform, ClinPx.

The 4D Q-plasia OncoReader Breast uses digitised pathology slides of breast cancer tissue to diagnose disease with improved accuracy, effectively acting as an aid for clinical histopathology experts.

“We believe that the integration of these two technologies will redefine how AI can be adopted by everyday pathologists,” says Rajendra Singh, M.D., founder of PathPresenter.

The primary purpose of integrating 4D’s proprietary algorithms within ClinPx is to potentially improve the throughput, reliability and quality of consultations provided by physicians. Additionally, users from pharmaceutical organisations could also benefit from the enablement of the standardised central pathology review of certain biomarkers within the context of clinical trials leveraging the ClinPx platform.

“This unique partnership is very much needed to make the most of the increasing investment in digital pathology,” says Tathagata Dasgupta, founder and president of 4D Path.

“While PathPresenter offers a software platform made by pathologists to serve pathologists in their digital workflow, it will have at its heart the 4D Path-driven end-to-end tumour profiling white-box solution that can produce synoptic reports to potentially assist clinical reporting.”

To advance the adoption of digital pathology worldwide, 4D Path and PathPresenter have also created educational content to teach current and future pathologists about how evaluation of breast cancer features prior to downstream genomic and molecular testing can potentially improve patient care.

In the UK, 4D Path has an existing partnership with the University of Leeds, after previously completing three breast cancer clinical studies with the university.